Research Day on Cancer
Lightning Talks |
| Susceptibility Richard Wein, Chieko Azuma, Catherine Freudenreich |
| Biomarkers Krishna Kumar, Amy Yee, Rong Shao |
| New Targets Al Charest, Philip Hinds, Brigitte Huber |
| Emerging Technologies Daniel Jay, Jonathan Garlick, Eric Miller |
Research Presentations |
| Insights into the Pathogenesis and Therapy of Human Leukemia through Studies in Mice Richard Van Etten |
| Elucidating the Origins of Human Breast Cancer Heterogeneity Charlotte Kuperwasser |
| Optical Mammography: Using Light to Detect Breast Cancer Sergio Fantini |
| Jean Mayer USDA Human Nutrition Research Center on Aging Auditorium |
| Poster Presentations and Reception |
| Jean Mayer USDA Human Nutrition Research Center on Aging Lobby, Mezzanine and Conference Room |
SusceptibilityModerated by Amy Yee |
| Risk Factors in the Development of Nasopharyngeal Carcinoma Richard Wein |
| Mapping Genes Associated with Spontaneous Canine Hemangioma and Expression Profiling: Potential Animal Model for Human Angiosarcoma Chieko Azuma |
| Chromosomal Fragile Sites: Why They Break and the Cancer Connection Catherine Freudenreich |
BiomarkersModerated by Catherine Freudenreich |
| Novel Carbohydrate Based Cancer Therapeutics and Imaging Agents Krishna Kumar |
| The HBP1 Transcriptional Repressor and Invasive Breast Cancer Mechanisms Amy Yee |
| A Cancer Biomarker YKL-40 Induces Tumor Angiogenesis Rong Shao |
New TargetsModerated by Jonathan Garlick |
| Genetic Dissection of EGFR Signaling Networks in Glioblastoma Al Charest |
| Cdk Inactivation Targets Tumor Initiating Cells Philip Hinds |
| Dipeptidyl Peptidase 2 as a Novel Prognostic Factor and Therapeutic Target in Chronic Lymphocytic Leukemia Brigitte Huber |
Emerging TechnologiesModerated by Philip Hinds |
| Light Inactivation Screen for Surface Proteins Required in Cancer Cell Invasion Daniel Jay |
| Engineered 3D, Human Tissue Platforms: Meeting the Needs of the Translational Pipeline in Cancer Discovery Jonathan Garlick |
| Ultrasound-based Guidance of HIFU Cancer Treatment Eric Miller |
| Sergio Fantini, PhD | ||
 | Professor of Biomedical Engineering and Associate Dean for Graduate Education in the School of Engineering at Tufts University. Professor Fantini’s research focus is in the area of biomedical optics, specifically in diffuse near-infrared spectroscopy and the imaging of biological tissues. His research laboratory has ongoing projects aimed at the noninvasive, functional imaging of the brain, the study of optical signatures of peripheral nerve activation, and the development of novel instrumentation for optical mammography. Professor Fantini’s lab has developed a novel approach to spectral imaging of the human breast that shows promise for the detection, diagnosis, and monitoring of breast cancer. | |
| Charlotte Kuperwasser, PhD | ||
 | Assistant Professor in the Department of Anatomy and Cellular Biology at Tufts University School of Medicine; investigator at the Molecular Oncology Research Institute, Tufts Medical Center. Dr. Kuperwasser’s lab works on breast cancer, with interests in the cellular origins of tumor formation, cancer progression, and metastasis. Dr. Kuperwasser has been working toward an understanding of the role of the tissue microenvironment in breast cancer metastasis and has developed a humanized animal model to identify cellular elements in the bone stroma (cell types, growth factors, matrix proteins) that promote tumor formation in sites distant from the primary tumor. | |
| Richard Van Etten, PhD | ||
 | Professor of Medicine, Tufts University School of Medicine; Chief, Division of Hematology/ Oncology, Tufts Medical Center; Interim Director, Tufts Medical Center Cancer Center. Dr. Van Etten’s laboratory studies the molecular pathogenesis of human leukemia. The Van Etten lab uses retroviral and transgenic technology to produce accurate and faithful mouse models of leukemia that can be used to identify and evaluate new treatment approaches. Their work was instrumental in identifying the BCR-ABL enzyme as the direct cause of chronic myeloid leukemia (CML). They subsequently identified one of the first ABL mutations that causes resistance to the anti-CML drug imatinib (Gleevec) and are currently testing new treatments for patients with drug-resistant CML. | |